Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
confirmed today that the U.S. Food and Drug Administration (FDA) has
cancelled Thursdays discussion of sugammadex at the Anesthetic and
Analgesic Drug Products Advisory Committee (AADPAC). Sugammadex sodium
injection is Mercks investigational medicine for the reversal of
neuromuscular blockade (NMB) induced by rocuronium or vecuronium.
Language:
English
Contact:
MerckMedia:Pam Eisele, 908-423-5042Sarra Herzog, 908-423-6154orInvestors:Carol Ferguson, 908-423-4465Justin Holko, 908-423-5088
Ticker Slug:
Ticker: MRK Exchange: NYSE
read more